Immune Function and the Progression to T1D
NCT05899439
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 1 Diabetes
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 0 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Florida
- Last updated on ClinicalTrials.gov
- April 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Kieran McGrail · Gainesville, FL
Ohio · 1
- The Ohio State University · Columbus, OH
Texas · 1
- Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.